Phase I trial of complement C1 inhibitor protein (C1-INH)

Trial Profile

Phase I trial of complement C1 inhibitor protein (C1-INH)

Phase of Trial: Phase I

Latest Information Update: 12 May 2015

At a glance

  • Drugs Complement C1 inhibitor protein (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions
  • Sponsors ProMetic Life Sciences
  • Most Recent Events

    • 12 May 2015 New trial record
    • 07 May 2015 ProMetic intends developing complement C1 inhibitor protein (C1-INH) for the treatment of hereditary angioedema and anticipates commencing this trial in the first half of 2016, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top